Date:3/12/2009

-- (34) (175) (756) NET LOSS $(3,807) $(29,261) $(52,881) $(90,062) NET LOSS PER COMMON SHARE Continuing operations $(0.08) $(0.67) $(1.17) $(2.05) Discontinued operations -- (--)* (0.01) (0.02) Basic and diluted net loss per common share $(0.08) $(0.67) $(1.18) $ (2.07) SHARES USED IN COMPUTING NET LOSS PER COMMON SHARE Basic and diluted 46,551,950 43,651,587 44,902,398 43,583,950 * Amount less than one cent.

    Balance Sheet Information (Unaudited):

                                         December 31,           December 31,
                                                2008                   2007
    Cash, cash equivalents, interest
     receivable and short-term
     investment securities                    $15,467                $62,386
    Long-term investment securities             7,185                  2,296
    Total assets                               26,634                 81,061
    Stockholders' (deficit) equity             (1,489)                44,422

'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint